Holen Sie sich die Stockscreener-App
69.78
0.11%
-0.08
Handel nachbörslich:
69.78
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$69.86
Offen:
$69.96
24-Stunden-Volumen:
4.93M
Relative Volume:
1.06
Marktkapitalisierung:
$41.16B
Einnahmen:
$6.60B
Nettoeinkommen (Verlust:
$4.16B
KGV:
10.07
EPS:
6.93
Netto-Cashflow:
$490.10M
1W Leistung:
-4.96%
1M Leistung:
-5.86%
6M Leistung:
-20.08%
1J Leistung:
-5.47%
1-Tages-Spanne:
$69.10
$70.28
1-Wochen-Bereich:
$68.23
$72.34
52-Wochen-Spanne:
$58.93
$96.12
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Vergleichen Sie EW mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
69.78 | 41.16B | 6.60B | 4.16B | 490.10M | 6.93 |
|
ABT
Abbott Laboratories
|
113.48 | 196.83B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
383.42 | 146.17B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
98.66 | 145.41B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
88.08 | 112.94B | 33.00B | 4.29B | 5.50B | 3.27 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
Edwards Lifesciences CVP Daniel Lippis sells $34,382 in stock - MSN
Seilern Investment Management Ltd Invests $109.49 Million in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Gateway Investment Advisers LLC Acquires 5,726 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Sees Significant Growth in Short Interest - MarketBeat
Boston Common Asset Management LLC Lowers Stock Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
65,442 Shares in Edwards Lifesciences Co. (NYSE:EW) Purchased by Avanza Fonder AB - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) VP Sells $34,380.00 in Stock - MarketBeat
Edwards Lifesciences CVP Daniel Lippis sells $34,382 in stock By Investing.com - Investing.com Canada
Wolfe Research Downgrades Edwards Lifesciences (EW) - MSN
Edwards Lifesciences exec sells $343,735 in stock - Investing.com
Do You Believe in the Growth Prospects of Edwards Lifesciences Corporation (EW)? - MSN
West Coast Financial LLC Sells 9,846 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Wolfe Research cuts Edwards Lifesciences stock rating to Underperform - MSN
Wolfe Research Downgrades Edwards Lifesciences (NYSE:EW) to Underperform - MarketBeat
Should Edwards Lifesciences Stock Stay in Your Portfolio Now? - Yahoo Finance
Meril successful at EPO against Edwards Lifesciences in heart-valve battle - JUVE Patent
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Assenagon Asset Management S.A. Buys 3,506,886 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST Purchases 300,000 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences price target raised to $74 from $72 at Bernstein - MSN
Edwards Lifesciences’ Q4 2024 Earnings: What to Expect - Nasdaq
Edwards Lifesciences’ Q4 2024 Earnings: What To Expect - Barchart
Edwards Lifesciences Co. (NYSE:EW) Receives $79.40 Consensus Target Price from Analysts - MarketBeat
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences Stock Price | EW Stock Quote, News, and History - Markets Insider
Brain Ischemia Market grow at CAGR of 7.6% Growth, Reaching $1,622 million by 2032 Globally - GlobeNewswire Inc.
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Nordea Investment Management AB Grows Stock Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) is largely controlled by institutional shareholders who own 85% of the company - Yahoo Finance
Edwards Lifesciences price target raised to $75 from $69 at Evercore ISI - Yahoo Finance
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Edwards Lifesciences (NYSE:EW) Share Price Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat
Edwards Lifesciences gets FDA warning letter - Reuters
Edwards Lifesciences Corporation (EW): Among the Cheap Healthcare Stocks to Buy Heading Into 2025 - Insider Monkey
Edwards Lifesciences Corp. stock rises Tuesday, still underperforms market - MarketWatch
Wolfe Research Upgrades Edwards Lifesciences (EW) - MSN
Edwards Lifesciences Corp. stock remains steady Monday, underperforms market - MarketWatch
Principal Financial Group Inc. Has $53.95 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Corporation's (NYSE:EW) Price Is Out Of Tune With Earnings - Simply Wall St
Jim Cramer: Is Edwards Lifesciences (EW) Poised for a Comeback? - Insider Monkey
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
EDWARDS ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Edwards lifesciences CVP Daniel Lippis sells $185k in stock By Investing.com - Investing.com Australia
Edwards lifesciences CVP Daniel Lippis sells $185k in stock - Investing.com India
Edwards Lifesciences' SWOT analysis: stock outlook amid TAVR challenges and TMTT growth - Investing.com
Daniel J. Lippis Sells 2,500 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock - MarketBeat
Assessing Edwards Lifesciences: Insights From 20 Financial Analysts - Benzinga
Edwards Lifesciences shares upgraded to buy, target lifted on trajectory - Investing.com
Bank of America Upgrades Edwards Lifesciences (NYSE:EW) to "Buy" - MarketBeat
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.31%
0.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):